---
title: "Shandong Boan Biotechnology Co., Ltd. (06955.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/06955.HK.md"
symbol: "06955.HK"
name: "Shandong Boan Biotechnology Co., Ltd."
industry: "Biotechnology"
---

# Shandong Boan Biotechnology Co., Ltd. (06955.HK)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | HK Market |
| Website | [www.boan-bio.com](https://www.boan-bio.com) |

## Company Profile

Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recur...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-17T04:30:10.000Z

**Overall: C (0.46)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 27 / 53 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 5.29% |  |
| Net Profit YoY | -48.10% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 2.12 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4.73B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 820.48M |  |


**Multi Score**: C

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 1.87% | C |
| Profit Margin | 4.23% | C |
| Gross Margin | 71.83% | A |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 5.29% | C |
| Net Profit YoY | -48.10% | D |
| Total Assets YoY | 37.28% | A |
| Net Assets YoY | 48.80% | A |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 2362.66% | A |
| OCF YoY | 5.29% | C |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.25 | D |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 40.80% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Shandong Boan Biotechnology Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "1.87%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "4.23%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "71.83%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "5.29%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-48.10%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "37.28%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "48.80%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "2362.66%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "5.29%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.25",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "40.80%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | BEONE MEDICINES (HK.6160) | C | A | B | C | A | B |
| 02 | INNOVENT BIO (HK.1801) | B | A | C | B | A | B |
| 03 | 3SBIO (HK.1530) | A | B | C | A | C | B |
| 04 | BIOCYTOGEN-B (HK.2315) | A | A | C | D | B | B |
| 05 | HBM HOLDINGS-B (HK.2142) | A | A | C | B | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 134.66 | 12/70 | 187.46 | 132.26 | 69.80 |
| PB | 2.12 | 13/70 | 3.99 | 3.09 | 2.56 |
| PS (TTM) | 5.70 | 14/70 | 9.98 | 7.65 | 6.28 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-07-24T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 0 | 0% |
| Hold | 1 | 100% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 7.60 |
| Highest Target | 10.46 |
| Lowest Target | 10.46 |

## References

- [Company Overview](https://longbridge.com/en/quote/06955.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/06955.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/06955.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.